Cumulative Clinical Trial Experience with Levofloxacin for Patients with Community-Acquired Pneumonia-Associated Pneumococcal Bacteremia

Clinical Infectious Diseases

Volumn 38, Issue SUPPL. 1, 2004, Pages

  Kahn, J B ^a   Bahal, N ^a   Wiesinger, B A ^a   Xiang, J ^a  

^a Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME AXETIL; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD SAMPLING; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MONOTHERAPY; MORTALITY; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 1642457384     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/378408     Document Type: Article

References (47)

1. Cassiere HA, Niederman MS. Community-acquired pneumonia. Dis Mon 1998; 44:613-75.
2. Gant V, Parton S. Community-acquired pneumonia. Curr Opin Pulm Med 2000; 6:226-33.
3. Lynch JP III, Martinez FJ. Community-acquired pneumonia. Curr Opin Pulm Med 1998; 4:162-72.
4. Marrie TJ. Pneumococcal pneumonia: epidemiology and clinical features. Semin Respir Infect 1999; 14:227-36.
5. Brown PD, Lerner SA. Community-acquired pneumonia. Lancet 1998; 352:1295-302.
6. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223-9.
7. Marrie TJ. Community-acquired pneumonia: epidemiology, etiology, and treatment. Infect Dis Clin North Am 1998; 12:723-40.
8. Watanakunakorn C, Bailey TA. Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992-1996: a detailed analysis of 108 cases. Arch Intern Med 1997; 157:1965-71.
9. Mufson MA. Pneumococcal pneumonia. Curr Infect Dis Rep 1999; 1: 57-64.
10. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine (Baltimore) 1990; 69:307-16.
11. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996; 275:134-41.
12. Kumar U, Rihawa A, Artinian VS, et al. Pneumococcal bacteremia associated with community-acquired pneumonia (CAP) in hospitalized patients [abstract 178]. In: Proceedings of the 40th Annual Meeting of the Infectious Diseases Society of America (IDSA). Alexandria, VA: IDSA, 2002.
13. Moroney JF, Fiore AE, Harrison LH, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001; 33:797-805.
14. Gutierrez F, Masia M, Rodriguez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003; 36:286-92.
15. Drinkovic D, Wong CG, Taylor SL, Roberts SA, Morris AJ. Pneumococcal bacteraemia and opportunities for prevention. N Z Med J 2001; 114:326-8.
16. Tilghman RC, Finland M. Clinical significance of bacteremia in pneumococcic pneumonia. Arch Intern Med 1937; 59:602-19.
17. Thompson RT, Ruegsegger JM, Blakenhorn MA, et al. Primary pneumonic pneumonia at the Cincinnati General Hospital, 1936-1950. J Lab Clin Med 1951; 37:73-87.
18. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60: 759-76.
19. Kramer MR, Rudensky B, Hadas-Halperin I, Isacsohn M, Melzer E. Pneumococcal bacteremia - no change in mortality in 30 years: analysis of 104 cases and review of the literature. Isr J Med Sci 1987; 23:174-80.
20. Plouffe JF, Breiman RF, Facklam RR. Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. Franklin County Pneumonia Study Group. JAMA 1996; 275:194-8.
21. Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30:520-8.
22. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-42.
23. Levaquin (levofloxacin) tablets; Levaquin (levofloxacin) injection; Levaquin (levofloxacin in 5% dextrose) injection [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceuticals, 2002.
24. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001; 119:1114-22.
25. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:747-50.
26. Empey PE, Jennings HR, Thornton AC, Rapp RP, Evans ME. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother 2001; 35:687-90.
27. Kays MB, Smith DW, Wack ME, Denys GA. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 2002; 22:395-9.
28. Kahn JB, Wiesinger BA, Xiang J. Macrolide-resistant Streptococcus pneumoniae in community-acquired pneumonia: clinical and microbiological outcomes for patients treated with levofloxacin. Clin Infect Dis 2003; 38(Suppl 1):S24-33 (in this issue).
29. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing: eighth informational supplement. Wayne, PA: NCCLS, 1998.
30. Ossowski EM. Pneumococcal vaccine failure. Am Fam Physician 1986; 34:175-7.
31. Schutze GE, Tucker NC, Mason EO Jr. Failure of the conjugate pneumococcal vaccine to prevent recurrent bacteremia in a child with human immunodeficiency virus disease. Pediatr Infect Dis J 2001; 20: 1009-10.
32. Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003; 3:71-8.
33. Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral β-lactams. J Antimicrob Chemother 2003; 51:691-6.
34. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35:556-64.
35. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31:1008-11.
36. Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000; 118:1839-40.
37. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000; 31:613-5.
38. Butler JC, Lennox JL, McDougal LK, Sutcliffe JA, Tait-Kamradt A, Tenover FC. Macrolide-resistant pneumococcal endocarditis and epidural abscess that developed during erythromycin therapy. Clin Infect Dis 2003; 36:e19-e25.
39. Lisby G, Brasholt MS, Teglbjerg MS. Bacteremia and meningitis caused by a macrolide-sensitive strain of Streptococcus pneumoniae during treatment with azithromycin. Clin Infect Dis 2001; 33:415-6.
40. Eng R, Maslow M, Brown S, et al. Breakthrough bacteremia in community-acquired pneumococcal pneumonia during treatment with oral antibiotics [abstract 555]. In: Proceedings of the 40th Annual Meeting of the IDSA. Alexandria, VA: IDSA, 2002.
41. Righter J. Pneumococcal meningitis during intravenous ciprofloxacin therapy. Am J Med 1990; 88:548.
42. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389-95.
43. Sahm DF, Karlowsky JA, Kelly LJ, et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob Agents Chemother 2001; 45:1037-42.
44. Zhanel GG, Walters M, Laing N, Hoban DJ. In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47:435-40.
45. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341:233-9.
46. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752-60.
47. Lister PD. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002; 44:43-9.